Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Intranasal RSVt vaccine in infants and toddlers
jRCT2031230744Phase 3Suspended
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, single-blind trial of RSVt vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Sanofi. Started Oct 2024; status: suspended.
02
Drugs
RSVt vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230744.